Follow-up of GI Cancers Dr. Marianne Taylor BC Cancer Agency – CSI November 29, 2003.

Slides:



Advertisements
Similar presentations
Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
Advertisements

Helical CT Screening for Lung Cancer at Advanced Radiology Consultants
Implementing NICE guidance
Implementing NICE guidance
Surveillance/ Screening Colonoscopy for Colorectal Cancer
LEFT HOLDING THE BAG? : CRC FOLLOW-UP CARE FOR FAMILY PHYSICIANS
Caring for patients in primary care after cancer treatments are done Moving Forward after Cancer Moving Forward after Cancer.
Diagnosis.
Cancer of Unknown Primary
CANCER SCREENING 2011 DELAWARE CANCER EDUCATION ALLIANCE STEPHEN S. GRUBBS, M.D. HELEN F. GRAHAM CANCER CENTER DELAWARE CANCER CONSORTIUM OCTOBER 5, 2011.
Colon lecture John R Pender, M.D. Dept. of Surgery BSOM, East Carolina University.
Taunton SpR Training Day 7th December 2012 Early rectal cancer
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Colon Cancer Basic Science 9/21/05. Colon and rectal neoplasms are characterized by: Consist of the third most common site of new cancer cases and deaths.
Matthew Kilmurry, M.D. St. Mary’s General Hospital Grand River Hospital.
Major sites of GIST metastases:
Management of GIST Dr Kwan Ming Wa Tuen Mun Hospital.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
AN INTRODUCTION TO PET-CT SCANNING Ray Murphy Chair – MCCN Partnership Group.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Eleni Galani Medical Oncologist
Colon Cancer Daniel A. Nikcevich, MD, PhD Duluth Clinic Cancer Center January 26, 2009.
High risk population in GI field how we can find them? Ahmad Shavakhi MD Associate professor of gastroenterology.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
How to manage suspected cancer
Colorectal carcinoma Dr.Mohammadzadeh.
Screening and Detection in Cancer Survivors
Colon Cancer First Page.
Colorectal cancer Khayal AlKhayal MD,FRCSC Assistant professor of Surgery Consultant Colorectal surgeon 9/11/2015Shwartz.
What are the usual sites of recurrence What are the usual sites of recurrence LocalLocal distantdistant Benefits Benefits Palliative chemo ± radiationPalliative.
Resection For Lung Metastases M62 Coloproctology Course.
Interventions for Clients with Colorectal Cancer
Slides last updated: June 2015 CRC: CLINICAL FEATURES.
Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.
Imaging Metastatic Rectal Cancer Jack Temple, MS3 June 2013 Christian Malalis, MD.
Post-treatment management of esophageal cancers: Surgical considerations Stephen Swisher, MD PhD Robert F. Fly Professor of Surgical Oncology Chairman,
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.
 Earliest possible diagnosis of the recurrence  Curative second-look surgery  Improved overall survival Follow-up The purpose of tumor markers.
COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.
Potentially curative re-resection of recurrent CRC  Suture line recurrences  Isolated liver metastases  Isolated pulmonary metastases.
Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.
Pathology Report Colorectal Cancer Sahar Najibi April 11 th, 2008.
T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.
Colon Cancer Matt Anderson, MD MSc Friday Teaching Seminar September 24, 2004.
Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Recent and evolving trends in breast and colon cancer by Jeff Kolbasnik.
Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Interventions for Clients with Colorectal Cancer.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
Towards Global Eminence K Y U N G H E E U N I V E R S I T Y Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society.
Colon Cancer Angela Lavrisiuk
Professor Dr. Sabeha Al-Bayati MBCHB,CABM,FRCP
Surgical Management of the Breast in Breast Cancer
1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)
تهیه کننده: استاد مربوطه: بهار 1392
What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases?
Systemic chemotherapy->chemoradiation->surgery.
Dr T P E Wells 13 July 2018 Breast SSG Bath
Neoadjuvant Adjuvant Curative Palliative
Presentation transcript:

Follow-up of GI Cancers Dr. Marianne Taylor BC Cancer Agency – CSI November 29, 2003

Introduction Purposes of follow-up Colorectal cancer Gastric cancer Esophageal cancer Pancreas cancer

Colorectal Cancer - Surveillance Primary goal is to discover isolated recurrence in lung, liver or bowel that is potentially curable with surgery ?Secondary goals – –Prevent second primary –Support patient –Start metastatic therapy earlier?? –Look for side effects of therapy

Colorectal Cancer – Surveillance Resectable liver metastases – 5yr survival 25-30% Resectable lung metastases – 5 yr survival 25-30% Isolated rectal recurrence – 20% 5 yr. Survival (Tepper et al. J Clin Oncol. 2003)

Colorectal Cancer – Surveillance Risk of a second primary –Cancer risk 5.3% in five years ( Togashi et al. Dis Colon Rectum 2000 ) –Risk of polyps is higher –Polypectomy can prevent development of cancer (National Polyp Study)

Levels of Evidence I.Meta-analysis and good RCT (high power) II.At least one well designed trial or RCT with low power III.Well designed but quasi-experimental trials cohort, case-control studies IV.Comparative and case studies V.From case reports and clinical examples

ASCO & BCCA Guidelines 1.History and physical exam every 3-6 months x 3yrs then annually BCCA- every 3mos x 3yrs then annually –Level V 2.CEA – only if surgery will be considered Q2-3 months for  2yrs BCCA guideline –q3mos. X 3 yrs –Level II J. Clin Oncol – 20:

ASCO & BCCA Guidelines 3.Colonoscopy – pre or post-op then q3-5 yrs (level I) Ba enema & sigmoidoscopy 4.Liver function testing – NR (level IV) 5.FOBT – NR (level II) 6.CT scan – NR (level II) 7.CXR – NR (level II) J. Clin Oncol – 20:

ASCO & BCCA Guidelines 8.Proctosigmoidoscopy – only if no XRT No interval suggested (level IV) If XRT colonoscopy as usual 9.Pelvic imaging – NR (level IV) 10.CBC – NR (level IV) J. Clin Oncol – 20:

ASCO & BCCA Guidelines Summary: Do: –History and physical –CEA –Colonoscopy –Investigate symptoms/signs as appropriate

ASCO & BCCA Guidelines Summary Don’t do: –CBC, liver tests, FOBT –Proctosigmoidoscopy unless no prior XRT –Pelvic imaging/ CT scan –CXR

Gastric Cancer Very early cancers (musosa or submucosa +/- nodes) might benefit from follow-up gastroscopy ( 6 &18 mos then 2-3 yr. Intervals) No evidence to support any follow-up in those with more advanced disease –Clinical follow-up only with investigations directed by symptoms/signs

Esophageal Cancer No evidence to support imaging/gastroscopy/BW Symptomatic follow-up only High propensity in XRT patients for benign strictures – so consider early referral for dilatation

Anal Canal Carcinoma Primary therapy is chemoradiotherapy Salvage is possible with surgery (APR) Need to be monitored closely for recurrence/ spread –Q2mo X 2yrs, 6mos x 1yr then q yearly to 5 –Examine anus and inguinal nodes

Pancreas Cancer After curative surgery – clinical follow-up only Keep in mind that surgery only cures % –Have low index of suspicion for symptoms/signs – good palliative therapy is available

Summary - GI Follow-up More intensive follow-up helpful: Colorectal Anal canal carcinoma

Summary - GI Follow-up Clinical follow-up only: Stomach Esophagus Pancreas